The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis
Yanan Sun, Mohammad Abed, Mohammad Hassan Sohouli · 2025
Read The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis by Yanan Sun, Mohammad Abed, Mohammad Hassan Sohouli (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12860172.txt.
Introduction
Yanan Sun, Mohammad Abed, and Mohammad Sohouli gather trial evidence in a 2025 review on a class of weight-loss drugs. The drugs switch on a brain receptor called MC4R, which controls hunger. They drew special hope for obesity tied to rare genetic syndromes, where that hunger circuit is broken. Their wider effect on weight and heart risk factors was still unsure.
Following standard review rules, the team searched for clinical trials of these drugs, both randomized and single-arm. Twelve studies made the cut. Pooling them with a random-effects model showed a clear drop in body weight against placebo. The review also weighs blood pressure, blood fats, and sugar control, and probes whether small or uneven studies bend the result. The summary helps doctors judge where this drug class fits.
Catalog record
| CREATOR | Yanan Sun, Mohammad Abed, Mohammad Hassan Sohouli |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis Authors: Yanan Sun, Mohammad Abed, Mohammad Hassan Sohouli Published: 2025 ABSTRACT AbstractBackgroundThe melanocortin-4 receptor (MC4R) agonists have emerged as potential treatments for obesity, particularly in patients with rare genetic syndromes. However, their overall effects on obesity and cardiometabolic risk factors remain uncertain. To systematically evaluate the efficacy of MC4R agonists on weight-related outcomes and cardiometabolic risk factors.MethodsWe conducted this study following PRISMA 2020 guidelines. Eligible studies included clinical trials ((RCTs and single-arm trials) of the effects of MC4R agonist drugs on anthropometric factors and cardiovascular risk factors. Random model effects meta-analyses were performed for this meta-analysis, with heterogeneity and small-study effects explored through sensitivity and publication bias analyses.ResultsA total of 12 studies were included. Treatment with MC4R agonists significantly reduced body weight compared with placebo in RCTs (WMD − 5.07 kg; 95% CI − 8.13 to − 2.02), with even larger reductions in single-arm studies (–11.23%; 95% CI − 15.43 to − 7.04). MC4R agonists also lowered BMI by − 13.67% (95% CI − 17.21 to − 10.12), waist circumference by − 11.75 cm, BMI Z-score by − 0.98, and hunger scores by − 3.38. These agents reduced triglyceride levels by − 35.53 mg/dL and LDL-C levels by − 9.14 mg/dL, while HDL-C levels showed a nonsignificant increase of + 2.37 mg/dL. Systolic blood pressure declined by − 4.38 mmHg, while diastolic pressure showed no meaningful change.ConclusionsMC4R agonists produce clinically meaningful weight reduction and improvements in several cardiometabolic risk factors. These findings support MC4R agonists as a promising therapy for genetic forms of obesity, while their role in nonspecific obesity requires confirmation in large, long-term randomized trials.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13098-025-02071-2.Keywords: Obesity, Melanocortin-4 receptor, MC4R agonists, Setmelanotide, Weight loss, Systematic review, Meta-analysis Introduction Obesity is a chronic, relapsing, and multifactorial disease linked with substantial morbidity, mortality, and healthcare costs globally. The prevalence of obesity has more than tripled over the past four decades, with more than 650 million adults classified as obese in 2016 according to the World Health Organization [1, 2]. Obesity is significantly linked to type 2 diabetes, cardiovascular disease, dyslipidemia, hypertension, nonalcoholic fatty liver disease, specific cancers, and reduced quality of life, making it one of the leading preventable causes of morbidity and premature mortality [3–5]. Although there have been improvements in lifestyle and behavioral interventions, weight loss is often modest and difficult to sustain, while bariatric surgery, though effective, is invasive and not universally accessible [4, 6]. These challenges highlight the urgent need for safe, effective, and durable pharmacological treatment strategies. The central melanocortin pathway is crucial for maintaining energy balance and appetite regulation. Within this pathway, the melanocortin-4 receptor (MC4R), a G-protein–coupled receptor expressed in the hypothalamus, is critical for integrating peripheral energy status signals and regulating satiety and energy expenditure [7]. Genetic variants that influence MC4R or its upstream regulators, including pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), and the leptin receptor (LEPR), are the most common monogenic contributors to severe, early-onset obesity, underscoring the clinical relevance of this pathway [8]. Pharmacological activation of MC4R has therefore emerged as a rational therapeutic strategy, with potential applications in both rare genetic syndromes and more common forms of obesity. Multiple MC4R agonists, such as setmelanotide and other investigational agents, have been evaluated in both early- and late-phase clinical trials. Initial findings indicate that these drugs can induce clinically meaningful reductions in body weight, improve hunger-related patient-reported outcomes, and favorably influence metabolic parameters. Results have shown variability across different populations, study durations, dosing regimens, and comparator arms. Uncertainty persists concerning the consistency of metabolic effects, especially regarding glucose homeostasis, lipid profiles, and blood pressure regulation [9–11]. Furthermore, it is unclear whether metabolic benefits extend consistently to glucose homeostasis, lipid profile, and blood pressure regulation, or whether efficacy differs between genetically defined obesity and nonspecific obesity populations [12]. To address these knowledge gaps, we conducted a comprehensive systematic review and meta-analysis of randomized and non-randomized studies evaluating MC4R agonists. Our objective was to quantify their effects on weight-related and cardiometabolic outcomes, with a priori hypotheses that MC4R agonists would significantly reduce body weight and body mass index (BMI) compared with placebo or other comparators, and that they would provide additional benefits for lipid parameters and blood pressure. By synthesizing the available evidence, we aim to clarify the therapeutic potential of this class of agents and delineate priorities for future research. Methods Search strategy This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [13]. The review protocol was not prospectively registered in PROSPERO or any other database. The review process commenced in January 2025, and all methodological steps, including eligibility criteria, search strategy, and analysis plan, were predefined in accordance with PRISMA 2020. A comprehensive literature search was performed in PubMed/MEDLINE, Web of Science, Scopus, and Embase from inception to August 2025, with no restrictions on language or publication date. Gray literature, conference abstracts, and reference lists of relevant reviews and included studies were also manually screened to minimize the risk of missing eligible trials. Search terms combined both Medical Subject Headings (MeSH) and free-text words and were structured around three main domains: [1] intervention (“Melanocortin-4 receptor agonist” OR “MC4R agonist” OR “Setmelanotide” OR “LY2112688” OR “Bremelanotide” OR “other MC4R agonist agents”); [2] condition (“Obesity” OR “Overweight” OR “Metabolic risk factors” OR “Dyslipidemia” OR “Blood pressure”); and [3] study design (“Randomized controlled trial” OR “Clinical trial” OR “Single-arm trial” OR “Intervention study”)(see Supplementary Table S2). The search strategy was adapted for each database. Eligibility criteria Studies were considered eligible if they met the following criteria: Design: Randomized controlled trials (RCTs) or single-arm clinical trials. Design: Randomized controlled trials (RCTs) or single-arm clinical trials. Population: Participants of any age (children, adolescents, or adults) with obesity or overweight, with or without metabolic risk factors, were eligible for inclusion. Population: Participants of any age (children, adolescents, or adults) with obesity or overweight, with or without metabolic risk factors, were eligible for inclusion. Intervention: Treatment with an MC4R agonist, regardless of dose or duration. Intervention: Treatment with an MC4R agonist, regardless of dose or duration. Outcomes: At least one relevant endpoint related to obesity markers [body weight, BMI, waist circumference (WC), BMI z-score, hunger score], glucose metabolism [fasting blood sugar (FBS)], lipid parameters [low (LDL-C) and high (HDL-C) density lipoprotein-cholesterol, triglycerides (TG)], or blood pressure [Systolic and Diastolic blood pressure (SBP, DBP)]; and. Outcomes: At least one relevant endpoint related to obesity markers [body weight, BMI, waist circumference (WC), BMI z-score, hunger score], glucose metabolism [fasting blood sugar (FBS)], lipid parameters [low (LDL-C) and high (HDL-C) density lipoprotein-cholesterol, triglycerides (TG)], or blood pressure [Systolic and Diastolic blood pressure (SBP, DBP)]; and. Reporting: Studies reporting baseline and post-intervention data, or between-group differences (for RCTs). Reporting: Studies reporting baseline and post-intervention data, or between-group differences (for RCTs). The primary outcomes of this review were weight-related measures (body weight, BMI, waist circumference, BMI z-score, and hunger score). Cardiometabolic risk factors, including lipid parameters, fasting glucose, and blood pressure, were considered secondary outcomes. Exclusion criteria included: non-human studies, review articles, meta-analyses,